サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：バイオシミュレーションの世界市場：2022-2028年
市場調査レポート
商品コード
1123064

バイオシミュレーションの世界市場：2022-2028年

Global Biosimulation Market Research And Analysis, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 130 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
バイオシミュレーションの世界市場：2022-2028年
出版日: 2022年07月14日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオシミュレーションの市場規模は予測期間中に約16.0%のCAGRで成長すると予測されています。

同市場の成長を増大させている主な要因は、現代医薬の開発・普及が急務であることです。さらに、代理出産の増加傾向、インフラの整備、政府による医療費支出の増加も市場成長に大きく寄与している要因と推定されています。また、製薬会社やバイオテクノロジー企業によるR&D費の増加も市場成長の要因となっています。

当レポートでは、世界のバイオシミュレーションの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析

第4章 市場決定要因

  • 推進要因
  • 抑制要因
  • 機会

第5章 市場分析：区分別

  • 世界のバイオシミュレーション市場：用途別
    • 創薬
    • 医薬品開発
  • 世界のバイオシミュレーション市場：製品別
    • ソフトウェア
    • サービス
  • 世界のバイオシミュレーション市場：エンドユーザー別
    • バイオテクノロジーおよび製薬会社
    • CRO
    • 規制当局
    • その他

第6章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 企業プロファイル

  • Advanced Chemistry Development, Inc.
  • Cell Works Group, Inc.
  • Evidera（Pharmaceutical Product Development（PPD）, LLC）
  • Genomatica Inc.
  • GNS Healthcare
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • LeadInvent Pharma Inc.
  • Nuventra Pharma Sciences
  • Physiomics Plc
  • RHENOVIA Pharma
  • Rhenovia Pharma SAS
  • Rosa & Co. LLC
  • VeriSIM Life
図表

LIST OF TABLES

1. GLOBAL BIOSIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION,2020-2027 ($MILLION)

  • 2. GLOBAL BIOSIMULATION IN DRUG DISCOVERY MARKET RESEARCH AND FORECAST BY REGION,2020-2027 ($ MILLION)

3. GLOBAL BIOSIMULATION IN DRUG DEVELOPMENT MARKET RESEARCH AND FORECAST BY REGION,2020-2027 ($MILLION)

4. GLOBAL BIOSIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT, 2020-2027 ($MILLION)

5. GLOBAL BIOSIMULATION SOFTWARE MARKET RESEARCH AND FORECAST BY REGION, 2020-2027($MILLION)

6. GLOBAL BIOSIMULATION SERVICES MARKET RESEARCH AND FORECAST BY REGION, 2020-2027 ($MILLION)

7. GLOBAL BIOSIMULATION MARKET RESEARCH AND FORECAST BY END-USER,2020-2027 ($MILLION)

8. GLOBAL BIOSIMULATION IN BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES MARKET RESEARCH AND FORECAST BY REGION, 2020-2027($MILLION)

  • 9. GLOBAL BIOSIMULATION IN CROs MARKET RESEARCH AND FORECAST BY REGION, 2020-2027, ($ MILLION)
  • 10. GLOBAL BIOSIMULATION IN REGULATORY AUTHORITIES MARKET RESEARCH AND FORECAST BY REGION,2020-2027($ MILLION)

11. GLOBAL BIOSIMULATION IN OTHER END-USERS MARKET RESEARCH AND FORECAST BY REGION, 2020-2027 ($MILLION)

12. GLOBAL BIOSIMULATION MARKET RESEARCH AND FORECAST BY GEOGRAPHY, 2020-2027($MILLION)

  • 13. NORTH AMERICA BIOSIMULATION MARKET RESEARCH AND FORECAST BY COUNTRY, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICA BIOSIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICA BIOSIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICA BIOSIMULATION MARKET RESEARCH AND FORECAST BY END USER, 2020-2027 ($ MILLION)
  • 17. EUROPE BIOSIMULATION MARKET RESEARCH AND FORECAST BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. EUROPE BIOSIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2020-2027 ($ MILLION)
  • 19. EUROPE BIOSIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT 2020-2027, ($ MILLION)
  • 20. EUROPE BIOSIMULATION MARKET RESEARCH AND FORECAST BY END USER, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC BIOSIMULATION MARKET RESEARCH AND FORECAST BY COUNTRY, 2020-2027($ MILLION)
  • 22. ASIA-PACIFIC BIOSIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2020-2027($ MILLION)
  • 23. ASIA-PACIFIC BIOSIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT,2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC BIOSIMULATION MARKET RESEARCH AND FORECAST BY END USER,2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD BIOSIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD BIOSIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT, 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD BIOSIMULATION MARKET RESEARCH AND FORECAST BY END USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOSIMULATION MARKET SHARE BY APPLICATION,2020 VS 2027 (%)
  • 2. GLOBAL BIOSIMULATION MARKET SHARE BY PRODUCT 2020 VS 2027 (%)
  • 3. GLOBAL BIOSIMULATION MARKET SHARE BY END USER,2020 VS 2027 (%)
  • 4. GLOBAL BIOSIMULATION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027(%)

5. NORTH AMERICA BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

6. US BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

7. CANADA BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

  • 8. EUROPEAN BIOSIMULATION MARKET SIZE 2020-2027 ($ MILLION)

9. UK BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

10. FRANCE BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

11. GERMANY BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

12. ITALY BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

  • 13. SPAIN BIOSIMULATION MARKET SIZE,2020-2027 ($ MILLION)
  • 14. ROE BIOSIMULATION MARKET SIZE,2020-2027 ($ MILLION)
  • 15. ASIA PACIFIC BIOSIMULATION MARKET SIZE,2020-2027 ($ MILLION)
  • 16. INDIA BIOSIMULATION MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. CHINA BIOSIMULATION MARKET SIZE,2020-2027 ($ MILLION)
  • 18. JAPAN BIOSIMULATION MARKET SIZE,2020-2027 ($ MILLION)
  • 19. REST OF ASIA-PACIFIC BIOSIMULATION MARKET SIZE,2020-2027 ($ MILLION)

20. REST OF THE WORLD BIOSIMULATION MARKET SIZE,2020-2027 ($MILLION)

目次
Product Code: HIT-1001

Global Biosimulation Market Size, Share & Trends Analysis Report, By Application (Drug Discovery and Drug Development), By Product (Software and Services), By End-User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Regulatory Authorities, and Others) and Forecast, 2021-2027

The global biosimulation market is growing at a CAGR of nearly 16.0% during the forecast period. The major factors that are augmenting the growth of the market is urgency to develop and promote modern drugs. Furthermore, rising trend of surrogacy, growing infrastructure and increasing healthcare spending by government are also estimated to be the major factors that are contributing significantly towards the growth of the market. The growth of market is also attributed to increase in spending on R&D by pharmaceutical and biotechnology.

However, there are certain factors that are affecting the growth of the market. High cost of drugs and treatment, low accuracy rate of the treatment and lack of awareness among people in the untapped regions for the uses of drugs. In addition to this, the stringent government regulations can affect the market and can be the major hindrance for the growth of the market.

Segmental Outlook

The market is segmented on the basis of application, product and end-user. By application, the market is segmented into drug development, drug discovery and other applications. Further, based on the product segment, the market is segmented into software, services and external/contract services. Moreover, based on the end-user segment, the market is segmented into biotechnologies and pharmaceutical companies, drug discovery and drug development companies, education centers and research institutes, regulatory authorities and others.

Global Biosimulation Market Share by Application, 2019 (%)

Global Biosimulation Market Share by Application

Drug Development segment hold a significant market share in 2020. The drug development market growth is driven by increasing availability of modern drugs. The clinical trial services will further get increased when there are growing numbers in the R&D expenditure. The providers which develop drugs includes Simulation Plus, Genedata AG, Compugen, Certara, Evidara, Medtronic, Johnson & Johnson and many more. Further, effective drugs are expected to contribute to the market growth. For instance, in August 2020, Certara received and FDA approval for its Imbruvica drug after two trials made by the authority for the same.

Regional Outlooks

Global Bio-simulation market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is estimated to be the leading region in the global infertility market. Huge adoption of bio-simulation technologies and high healthcare spending are the factors contributing to growth of the market in the region. Asia Pacific is estimated to be the fastest growing region during the forecast period 2020-2027.

Global Biosimulation Market Growth, by Region 2020-2026

Global Biosimulation Market Growth, by Region

Asia-Pacific will have considerable growth in the global Bio-simulation market

The Asia-Pacific region is expected to create opportunities for the global market players due to rise in population in the emerging economies like China, Japan and India. Further, the government and non-government organizations will support the growth of new advanced drugs. The increase in awareness among people with time will also contribute to market's growth.

Market Players Outlook

Key players of the bio-simulation market are Certara, Dassault Systemes, Genedata AG, Johnson & Johnson, Simulation Plus, Schrodinger, Inc, Compugen, Physiomics Plc Rosa & Co. LLC, Rti Surgical, Leadinvent Pharma Inc, Medtronic, Nuventra Pharma Sciences, Advanced Chemistry Development . In order to survive in the market these players adopt different marketing strategies such as merger, acquisitions, product launch, and geographical expansion so on. For Example: In October 2019, Dassault Systemes acquired Medidata Solutions, Inc for enhancement in clinical trials and cloud-based solutions.

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global female infertility diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Dassault Systemes SE
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Schrodinger, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Genedata AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Certara Holding, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Simulations Plus
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Biosimulation Market by Application
    • 5.1.1. Drug Discovery
    • 5.1.2. Drug Development
      • 5.1.2.1. Preclinical Testing
      • 5.1.2.2. Clinical Trials
  • 5.2. Global Biosimulation Market by Product
    • 5.2.1. Software
      • 5.2.1.1. Pharmacokinetic/Pharmacodynamic (Pk/Pd) Modelling and Simulation Software
      • 5.2.1.2. Molecular Modelling andSimulation Software
      • 5.2.1.3. Physiologically Based Pharmacokinetic Modelling (Pbpk) Modelling andSimulation Software
      • 5.2.1.4. Toxicity Prediction Software
      • 5.2.1.5. Trial Design Software
    • 5.2.2. Services
      • 5.2.2.1. In-House
      • 5.2.2.2. Contract
  • 5.3. Global Biosimulation Market by End-User
    • 5.3.1. Biotechnology and Pharmaceutical Companies
    • 5.3.2. Contract Research Organizations (CROs)
    • 5.3.3. Regulatory Authorities
    • 5.3.4. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Advanced Chemistry Development, Inc.
  • 7.2. Cell Works Group, Inc.
  • 7.3. Evidera (Pharmaceutical Product Development (PPD), LLC)
  • 7.4. Genomatica Inc.
  • 7.5. GNS Healthcare
  • 7.6. In Silico Biosciences, Inc.
  • 7.7. INOSIM Software GmbH
  • 7.8. LeadInvent Pharma Inc.
  • 7.9. Nuventra Pharma Sciences
  • 7.10. Physiomics Plc
  • 7.11. RHENOVIA Pharma
  • 7.12. Rhenovia Pharma SAS
  • 7.13. Rosa & Co. LLC
  • 7.14. VeriSIM Life